GLP-1 RA exposure in early pregnancy not significantly tied to hypertensive disorders
GLP-1 Medications Show No Link to Pregnancy Hypertension Risk
This meta-analysis of observational cohort studies assessed the risk of hypertensive disorders of pregnancy (HDP) after periconceptional or …
A large review of over 10,000 pregnancies suggests that GLP-1 medications may not increase the risk of high blood pressure during pregnancy.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Tirzepatide Efficacy and Safety for Managing Type 2 Diabetes in Chinese Patients
Tirzepatide cuts blood sugar and weight in early diabetes
A Phase 3 trial demonstrates that weekly tirzepatide significantly reduces HbA1c levels and body weight in patients with early type 2 diabet…
A weekly shot lowered blood sugar by over 2% and helped people lose up to 22 pounds in 40 weeks.
Incretin-based therapies outperform placebo for glycemic control and weight loss in type 2 diabetes
Newer diabetes drugs outperform for blood sugar and weight loss
This network meta-analysis of 15 incretin-based therapies (IBTs) indicates that tirzepatide, orforglipron, and semaglutide provide superior …
A large analysis finds that newer incretin-based drugs like tirzepatide and semaglutide beat placebo for blood sugar and weight loss in type…
Tirzepatide at maximum tolerated dose achieved 21.9% bodyweight reduction over 112 weeks
Trial shows tirzepatide helps maintain weight loss over two years
This Phase 3b randomized controlled trial evaluated tirzepatide in 378 adults with obesity over a 112-week period. Patients receiving the ma…
A long-term study shows that tirzepatide can help people with obesity maintain significant weight loss for up to 112 weeks.
Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
New analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly
This systematic review and meta-analysis evaluated 15 782 adults with overweight or obesity receiving incretin-based therapies or intensive …
A large review of 15,782 adults found that weight loss drugs and lifestyle changes led to similar proportions of muscle loss during weight r…
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Tirzepatide improves waist-to-height ratio in adults with obesity or overweight
Tirzepatide improves waist-to-height ratio in obesity and prediabetes
A post-hoc analysis of a Phase 3 RCT found that tirzepatide (10/15 mg) improved waist-to-height ratio (WHtR) in adults with obesity or overw…
A new analysis finds tirzepatide helps more people with obesity achieve a healthier waist-to-height ratio, a key measure of belly fat risk.
Systematic review and meta-analysis of tirzepatide effects on HbA1c and weight in adults with type 2 diabetes
Tirzepatide lowers blood sugar and weight in real-world diabetes care
This systematic review and meta-analysis pooled data from real-world studies involving 89 296 adults with type 2 diabetes. Tirzepatide was a…
A large review of real-world data shows tirzepatide lowers blood sugar and helps people lose weight, matching results from clinical trials.
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …